FDA Approves Tzield (teplizumab) to Delay the Onset of Type 1 Diabetes 

We are excited to share that the FDA just approved the first-ever disease-modifying therapy for type 1 diabetes! It is called Tzield (teplizumab) and is indicated to delay the onset of type 1 diabetes in adults and pediatric patients aged 8 years and older who are at high risk of getting type 1.The type1tested.com website is a fantastic place to learn more about Tzield and the different screening options.